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Thus, we were able to calculate the
mean difference instead of the stan-
dardized mean difference of the param-
eters of interest (PAJV and AVA).
Although our results are similar to
those of the original meta-analysis,
even after including the SEAS study,
we have enclosed the correct method-
ology to arrive at the conclusion.
Deepak Vedamurthy, MD
Janos Molnar
Rohit Arora, MD
Chicago Medical School
Chicago, III
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Reply to the Editor:
We appreciate the comments by
Vedamurthy and associates1 on our
meta-analysis.2 The standardized
mean difference (SMD) is used as
a summary statistic in meta-analyses
when the studies all assess the same
outcome but measure it in a variety
of ways (eg, all studies measure de-
pression, but they use different psy-
chometric scales).3 Vedamurthy and
colleagues stated that there were
some errors in the calculation of the
summary estimate: the units for aortic
valve area (AVA) and peak aortic jet
velocity (PAJV) had been mixed in
the calculations. Similar summary esti-
mates, however, can be commonly
found in published meta-analyses. In
a meta-analysis of negative pressure
wound therapy,4 for instance, a change
in wound area per day (in square cen-
timeters), a change in wound area until
surgical closure (in square centime-
ters), and a relative change in wound
area until surgical closure or hospital
discharge (in percentages) were com-
bined by using the SMD method.
Although Vedamurthy and associates1
projected the AVA and PAJV change
per year by using the baseline values
and percentage change data expressed
in the original articles, precise calcula-
tion methods were not mentioned.
Was the mean of the absolute change
in the AVA or PAJV calculated by
multiplying the mean of the baseline
value by the mean of the percentage
change? It is mathematically obvious,
however, that the mean of the absolute
change is not equal to the product of
the mean of the baseline value by the
mean of the percentage change. Fur-
thermore, how was the standard devia-
tion (SD) of the change in the AVA or
PAJV? The SD of the absolute change
also cannot be equal to the product of
the mean of the baseline value by the
SD of the percentage change. We do
not have the slightest doubt that the
SMD method using the absolute and
percentage changes themselves ex-
pressed in the original article is better
than the simple mean difference
method using the absolute changes
that are complexly calculated by
authors of a meta-analysis. However,
we would like to know how Vedamur-
thy and associates calculated the mean
or SD of the absolute change.
Hisato Takagi, MD, PhD
Takuya Umemoto, MD, PhD
Department of Cardiovascular
Surgery
Shizuoka Medical Center
Shizuoka, Japan
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To the Editor:
We read with interest the comments
of Zegdi and colleagues1 on our
article entitled ‘‘Surgical aortic valve
replacement after percutaneous aortic
valve implantation: what have we
learned?’’2 The authors raised several
important questions about transcath-
eter heart valve (THV) size selection
according to the aortic annular diame-
ter and the issue of oversizing. In the
case reported a 23-mm balloon ex-
pandable Cribier–Edwards THV had
been selected for an aortic annulus
measured to 20 mm by using echocar-
diographic analysis (2 mm of oversiz-
ing), which was in agreement with the
Edwards company’s recommenda-
tions. After THV implantation, it
clearly appeared that the THV size
was too small, explaining the subse-
quent severe paravalvular leak leading
to surgical valve replacement.
Retrospectively, it seems that
the transthoracic echocardiographic
(TTE) and transesophageal echocar-
diographic (TEE) measurements defi-
nitely underestimated the annular
diameter. A 26-mm THV size should
have been implanted in this patient,
as in any similarly tall male patient.
The lack of annular ring in the stented
THV device might explain the differ-
ence with the bioprosthesis size (23
mm) surgically implanted in this pa-
tient. The accuracy of annular size
echocardiographic measurement is
a technical issue, which has been
solved thereafter. This patient was
our second case included in the first
multicenter European Registry of En-
dovascular Implantation of Valves iny c Volume 138, Number 5 1255
Europe (REVIVE) trial in 2007, and
we must admit that since then, we
have learnt a lot about annular size
measurement by means of echocar-
diographic analysis.
A precise measurement of the annu-
lar size is definitely crucial to avoid
THV/annulus mismatch, and the
assessment still relies on the annular
diameter measurement obtained by
means of TTE, TEE, or both in the
long-axis view at the leaflet insertion
site. Thiswas not clear enough in 2007.
The authors say that a ‘‘dramatic in-
cidence of severe aortic regurgitation’’
was noted in our first pioneering expe-
rience with the antegrade transseptal
approach, but this was due to the
unique 23-mm THV available at that
time. The incidence of severe leaks
has markedly decreased thereafter
with the launch of the 26-mm THV,
the refinement of the screening pro-
cess, and the availability of the trans-
apical approach in case of suboptimal
femoroiliac access (4.7% of grade
2 aortic regurgitation in the latest
European Source Registry, 2009).
The updated THV size recommenda-
tions are as follows: 23-mm THV for
an annulus of 18 to 21 mm (2–5 mm
of oversizing) and 26-mm THV for
an annulus of 21 to 25 mm (1–5 mm
of oversizing). Selecting the THV
size is thus easy when the diameter is
found to be less than 20 mm or greater
than 22 mm but might still be an issue
in intermediate cases.
Even in experienced hands, the pre-
cision of echocardiographic measure-
ments is not perfect. TTE, which is
used by many investigators, is sup-
posed to be less accurate than TEE,
and generally measures a diameter
smaller by 1 mm. Additional tools
can be used when the diameter is
found to be nearly 21 mm, but com-
puted tomographic scanning and mag-
netic resonance imaging are not
reliable and overestimate the annular
size by 2 or 3 mm. In borderline cases
the best solution seems now to
combine valve predilatation with
a 23-mm balloon and simultaneous su-
pra-aortic angiographic analysis,
which is actually routinely done. The
observed gap between balloon sides
and the aortic wall, as well as any
degree of aortic regurgitation at full
balloon inflation, are very helpful to
determine the optimal THV size.
These approaches are actually very
effective, as assessed by the marked
decrease in severe aortic regurgitation.
Pierre-Yves Litzler, MD, PhD
Alain Cribier, MD
Departments of Cardiovascular
Surgery and Cardiology
Inserm 644
Hopital Charles Nicolle
Rouen University
Rouen, France
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